Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: $AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amneal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amneal Pharmaceuticals's position in the market.
Amneal Pharmaceuticals, Inc. reported a Q1 2024 net revenue of $659 million, with a GAAP net loss of $92 million and diluted loss per share of $0.30. Adjusted EBITDA was $152 million with adjusted diluted EPS of $0.14. The company settled a nationwide opioids case and affirmed its 2024 full-year guidance.
